Plozalizumab
Plozalizumab' (INN: hu1D9) is a humanized monoclonal antibody developed for the treatment of conditions such as diabetic nephropathy and maintaining arteriovenous graft patency. Developed by Takeda Pharmaceuticals International Co., plozalizumab represents a significant advancement in the management of complications associated with diabetes and dialysis.
Mechanism of Action
As a humanized monoclonal antibody, plozalizumab targets specific pathways involved in the progression of diabetic nephropathy and the failure of arteriovenous grafts. While the exact targets and mechanisms may vary, monoclonal antibodies like plozalizumab are designed to modulate immune responses or block pathological processes at the molecular level.
Indications
- Diabetic nephropathy: A serious complication of diabetes characterized by kidney damage due to long-standing high blood sugar levels.
- Arteriovenous graft patency: Maintenance of open and functional arteriovenous grafts used in dialysis for patients with kidney failure.
Development
Plozalizumab's development by Takeda Pharmaceuticals International Co. underscores the pharmaceutical industry's commitment to addressing complex medical conditions with innovative biologic treatments. Humanized monoclonal antibodies represent a growing area of therapeutic development, offering targeted interventions for diseases with significant unmet medical needs.
Related Terms
- Humanized monoclonal antibody: A monoclonal antibody that is modified to contain mostly human antibody sequences, minimizing the immune response against the antibody when used in patients.
- Diabetic nephropathy: Kidney damage resulting directly from long-term diabetes.
- Arteriovenous graft: A surgical connection made between an artery and a vein, used primarily for the purpose of hemodialysis.
External links
- Medical encyclopedia article on Plozalizumab
- Wikipedia's article - Plozalizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski